newsfilter
← Latest News
GlobeNewswire·

RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th

  • RenovoRx, Inc. (NASDAQ: RNXT) CEO Shaun Bagai will present at the iAccess Alpha Virtual Best Ideas Winter Investment Conference on December 9-10, 2025.
  • Bagai's specific presentation is scheduled for Tuesday, December 9 at 12:30 P.M. ET.
  • The Company reported year-to-date revenue of approximately $900,000 as of September 30, 2025, driven by commercial sales of RenovoCath.
  • Growth in clinical demand & adoption of RenovoCath as a standalone device is observed across new & repeat customers, including National Cancer Institute-designated centers.
  • The presentation will cover the ongoing Phase III TIGeR-PaC clinical trial for intra-arterial gemcitabine delivered via RenovoCath (IAG) in locally advanced pancreatic cancer.
  • Updates will be provided on a post-marketing registry study capturing real-world data on RenovoCath safety & effectiveness for solid tumors.
  • Investor-initiated trials in borderline resectable & oligometastatic pancreatic cancer are underway to expand the TAMP™ therapy platform application.
  • RenovoCath is an FDA-cleared device for isolating blood flow, delivering fluids, & temporary vessel occlusion.
  • IAG received Orphan Drug Designation for pancreatic cancer & bile duct cancer, granting seven years of market exclusivity upon approval.
  • A webcast of the presentation is available at https://ir.renovorx.com/news-events/ir-calendar-events, with a replay to follow on the Company's website.
  • One-on-one investor meetings with Bagai can be scheduled by contacting KCSA Strategic Communications at RenovoRx@KCSA.com.